Immunovaccine to Present at 2017 Biotech Showcase Conference
(firmenpresse) - HALIFAX, NOVA SCOTIA -- (Marketwired) -- 01/04/17 -- Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it will participate in the in San Francisco, CA. This event takes place January 9-11, 2017, at the Hilton San Francisco Union Square.
is scheduled to present a corporate overview and update on Monday, January 9, at 9:00 a.m. PT in Room 8. The presentation will be available on Immunovaccine''s website at following the meeting.
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company''s DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1/1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at .
Contacts:
MEDIA
Mike Beyer
Sam Brown Inc.
(312) 961-2502
INVESTOR RELATIONS
Frederic Ors
Chief Executive Officer
(902) 492-1819
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.01.2017 - 06:05 Uhr
Sprache: Deutsch
News-ID 1478496
Anzahl Zeichen: 3797
contact information:
Contact person:
Town:
HALIFAX, NOVA SCOTIA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 228 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunovaccine to Present at 2017 Biotech Showcase Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunovaccine Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
